Increasing childhood obesity and young-onset diabetes have made clinically distinguishing between type 1 diabetes (T1D) and type 2 diabetes (T2D) more difficult. A Genetic risk score (GRS) for T1D was developed in European populations, with good discrimination of diabetes type. Here, we aim to evaluate T1D-GRS in a Han-Chinese cohort. We utilized whole genome genotyping data for 533 nondiabetic controls, 182 patients with T1D, and 6,209 patients with T2D. We computed the T1D-GRS for each subject using 30 T1D associated SNPs. The mean ages of the controls, T1D, and T2D subjects were 47±11, 32±15, and 57±13 years, respectively. Violin plots of the GRS for the 3 groups are shown in the Figure, along with p-values. The mean GRS across the controls, T1D, and T2D were 0.242, 0.256, and 0.242, respectively. The area under the curve (AUC) for GRS in T1D vs. T2D was 0.677 (95% CI: 0.635-0.718), and 0.678 (95% CI: 0.631-0.725) for T1D patients vs. controls. We conclude that T1D-GRS detects significant differences in T1D genetic risk between T1D and non-T1D in a Han-Chinese population, with subjects with T1D having a higher score. Further refinement incorporating single nucleotide polymorphisms (SNPs) specific for a Han-Chinese population is currently underway, and is expected to further improve classification of T1D in Han-Chinese.
R. Wan: None. S.A. Sharp: None. C.H.T. Tam: None. M.N. Weedon: None. J.C. Chan: None. W. Hagopian: Consultant; Self; Novo Nordisk Inc. R.A. Oram: None. R.C. Ma: Advisory Panel; Self; AstraZeneca. Stock/Shareholder; Self; GemVCare. Other Relationship; Self; AstraZeneca, Bayer Healthcare Pharmaceuticals Inc., Merck & Co., Inc., Novo Nordisk A/S, Pfizer Inc., Sanofi-Aventis, Tricida Inc.
Research Grants Council (T12-402/13N); Research Impact Fund (CUR4012-18)
